News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
2,786 Results
Type
Article (26)
Press Release (2760)
Section
Business (1332)
Career Advice (2)
Deals (180)
Drug Development (628)
FDA (94)
Job Trends (267)
News (2098)
Policy (116)
Tag
Academia (3)
Alliances (38)
Alzheimer's disease (21)
Approvals (93)
Asia (310)
Australia (12)
Bankruptcy (1)
Best Places to Work (271)
C2C Services and Suppliers (38)
California (14)
Canada (5)
Cancer (11)
Career advice (1)
China (2)
Clinical research (573)
Compensation (1)
COVID-19 (4)
Data (11)
Delaware (4)
Diagnostics (17)
Earnings (1300)
Europe (541)
Events (302)
FDA (96)
Florida (3)
Gene therapy (1)
GLP-1 (6)
Government (8)
Healthcare (85)
Hotbed/Location (2070)
Indiana (7)
Infectious disease (4)
Inflammatory bowel disease (1)
IPO (160)
Job creations (1)
Job search strategy (1)
Layoffs (1)
Legal (1)
Lung cancer (7)
Manufacturing (1)
Maryland (2)
Massachusetts (13)
Medical device (56)
Medtech (56)
Mergers & acquisitions (21)
Metabolic disorders (1)
Minnesota (1)
Multiple sclerosis (1)
Neuroscience (22)
New Jersey (7)
New York (10)
NextGen Class of 2024 (8)
Non-profit (4)
North Carolina (4)
Northern California (11)
Obesity (1)
Ohio (1)
Pennsylvania (8)
People (8)
Phase I (85)
Phase II (169)
Phase III (338)
Pipeline (9)
Postmarket research (27)
Preclinical (10)
Prostate cancer (1)
Rare diseases (2)
Regulatory (115)
Reports (2)
Research institute (6)
Resumes & cover letters (1)
South America (5)
Southern California (4)
Startups (3)
United States (76)
Utah (2)
Vaccines (1)
Washington State (2)
Date
Today (7)
Last 7 days (11)
Last 30 days (18)
Last 365 days (412)
2024 (288)
2023 (423)
2022 (418)
2021 (481)
2020 (310)
2019 (202)
2018 (150)
2017 (116)
2016 (39)
2015 (73)
2014 (43)
2013 (25)
2012 (28)
2011 (23)
2010 (22)
2,786 Results for "%E2%80%9D%20target=".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
September 16, 2024
·
19 min read
Press Releases
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
September 16, 2024
·
17 min read
Press Releases
Tigermed Reports 2024 Interim Results
August 28, 2024
·
9 min read
Press Releases
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
August 15, 2024
·
12 min read
Press Releases
Regeneron Reports Second Quarter 2024 Financial and Operating Results
August 1, 2024
·
30 min read
Press Releases
Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis
September 13, 2024
·
13 min read
Press Releases
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
August 9, 2024
·
12 min read
Press Releases
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
September 9, 2024
·
32 min read
Press Releases
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
August 20, 2024
·
34 min read
Drug Development
Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
July 17, 2024
·
13 min read
1 of 279
Next
